Key Events This Week
15 Sep: Stock opens at Rs.1,325.05, down 6.26% amid broad market weakness
16 Sep: Fredun hits lower circuit at Rs.1,197.70, down 9.8%, amid panic selling
16 Sep: Valuation shifts from expensive to fair, with improved P/E and EV multiples
18 Sep: Stock recovers modestly to Rs.1,305.85, closing the week down 7.62%
15 September 2026: Weak Start Amid Market Downturn
Fredun Pharmaceuticals opened the week at Rs.1,325.05 on 15 Sep, registering a sharp decline of 6.26% from the previous Friday’s close of Rs.1,413.55. This drop coincided with a broader market sell-off, as the Sensex fell 1.69% to 35,169.62. The stock’s volume was moderate at 18,185 shares, reflecting cautious investor sentiment. The decline was sharper than the benchmark, signalling early signs of pressure specific to Fredun despite the overall market weakness.
16 September 2026: Lower Circuit Triggered Amid Heavy Selling
On 16 Sep, Fredun Pharmaceuticals faced intense selling pressure, hitting its lower circuit limit at Rs.1,197.70, a 9.8% drop from the previous close. The stock traded in a wide intraday range from Rs.1,345.80 to Rs.1,195.20 before settling near the day’s low. This marked the maximum permissible daily decline, reflecting panic selling and unfilled supply overwhelming demand. The volume surged to 30,183 shares, with turnover reaching ₹9.25 crore, indicating moderate liquidity for a micro-cap stock.
In stark contrast, the Sensex gained 0.30% to 35,276.25, underscoring that Fredun’s plunge was driven by company-specific factors rather than market trends. The stock’s technical position deteriorated further as it traded below all key moving averages, signalling a sustained downtrend. Delivery volumes also declined by over 31% compared to the prior five-day average, highlighting waning investor commitment.
Valuation Shift Signals Renewed Price Attractiveness
Despite the sharp price fall, Fredun Pharmaceuticals’ valuation profile improved significantly during the week. The company’s price-to-earnings (P/E) ratio adjusted to 50.01, moving from an expensive to a fair valuation grade. This shift is notable given the sector’s typical valuation ranges and Fredun’s historical multiples. The price-to-book value (P/BV) stood at 7.86, consistent with premium valuations for pharmaceutical firms with strong growth prospects.
Enterprise value multiples further supported this improved valuation stance, with EV to EBIT at 23.36 and EV to EBITDA at 21.23. These figures, while premium, align with Fredun’s robust operational profitability and efficient capital utilisation. Compared to peers such as Ind-Swift Laboratories and Shukra Pharmaceuticals, which trade at very expensive multiples, Fredun’s fair valuation grade suggests a more balanced price point relative to earnings and cash flow.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
17 September 2026: Partial Recovery on Positive Market Sentiment
Fredun Pharmaceuticals rebounded on 17 Sep, gaining 4.67% to close at Rs.1,278.65. This recovery followed the previous day’s sharp decline and was accompanied by increased volume of 32,462 shares. The broader market also advanced, with the Sensex rising 0.46% to 35,439.31. The stock’s bounce back, however, was insufficient to offset the prior losses, and it remained below key moving averages, indicating ongoing technical challenges.
18 September 2026: Modest Gains Close Out Volatile Week
On the final trading day of the week, Fredun Pharmaceuticals added 2.13% to close at Rs.1,305.85, recovering some ground but still ending the week down 7.62%. Volume declined to 16,359 shares, reflecting reduced trading activity. The Sensex continued its upward trend, gaining 0.52% to 35,625.23. Despite the modest gains, the stock’s weekly performance lagged the benchmark by over 7 percentage points, highlighting the impact of company-specific volatility.
Want to dive deeper on Fredun Pharmaceuticals Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Daily Price Comparison: Fredun Pharmaceuticals vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-15 | Rs.1,325.05 | -6.26% | 35,169.62 | -1.69% |
| 2026-09-16 | Rs.1,197.70 | -9.80% | 35,276.25 | +0.30% |
| 2026-09-17 | Rs.1,278.65 | +4.67% | 35,439.31 | +0.46% |
| 2026-09-18 | Rs.1,305.85 | +2.13% | 35,625.23 | +0.52% |
Key Takeaways
Significant Volatility: The week was characterised by sharp price swings, including a lower circuit hit on 16 Sep, reflecting intense selling pressure and investor uncertainty.
Valuation Improvement: Despite the price weakness, Fredun’s valuation metrics shifted favourably from expensive to fair, supported by improved P/E and EV multiples relative to peers.
Technical Weakness: The stock remains below key moving averages with declining delivery volumes, indicating ongoing technical challenges and cautious investor sentiment.
Relative Underperformance: Fredun underperformed the Sensex by over 7 percentage points for the week, highlighting company-specific headwinds amid a broadly stable market.
Strong Fundamentals: The company’s upgraded Mojo Score of 80.0 and Strong Buy grade reflect robust financial metrics and growth prospects despite short-term price volatility.
Conclusion
Fredun Pharmaceuticals Ltd’s week was defined by a dramatic price correction culminating in a lower circuit event, followed by a partial recovery and a positive shift in valuation parameters. While the stock’s technical outlook remains challenged, the improved valuation and strong fundamental scores suggest that the recent sell-off may be driven more by short-term sentiment than by deteriorating business conditions. Investors should monitor volume trends and price action closely in the coming sessions to gauge potential stabilisation. The divergence between Fredun’s performance and the broader market underscores the importance of company-specific factors in driving micro-cap stock volatility.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
